LUDWIG ENTERPRISES, INC.

LUDG
About the company

Ludwig Enterprises, Inc. operates as a genomic technology focused on developing testing approaches for inflammation-related chronic diseases, including cancers in the United States. The company integrates mRNA inflammatory biomarkers, proprietary machine-learning algorithms, and at-home cheek swab collection kits for cancer identification.

Country: United StatesPrice: $0.00Market Cap: $668,667

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

2 / 14

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 16 investors flag at least one profitability criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedFAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2025 · Balance sheet at 2026-03-31

Latest source filing: 2026-05-29

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-03-31

Latest source filing: 2026-05-29

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-03-31 · TTM ended 2026-03-31

Latest source filing: 2026-05-29

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-16

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-16

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-03-31 · Balance sheet at 2026-03-31 · Market data at 2026-11-01

Latest source filing: 2026-05-29

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-03-31 · Balance sheet at 2026-03-31

Latest source filing: 2026-05-29

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-16

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-03-31

Latest source filing: 2026-05-29

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-16

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-03-31 · Balance sheet at 2026-03-31 · Market data at 2026-11-01

Latest source filing: 2026-05-29

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-03-31

Latest source filing: 2026-05-29

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-16

Score computed: 2026-11-14

TTM ended 2026-03-31 · Balance sheet at 2026-03-31 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-05-29

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-16

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-03-31

Latest source filing: 2026-05-29

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-03-31 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-05-29

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Profitability0% pass✓ 2✗ 33▾

      No clean pass — all 16 investors flag at least one profitability criterion

      Positive EPS (10 years)0/5 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/5 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)
      ✗BuffettStable or rising over 10 years
      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROEN/A (negative equity)
      ✗Lynch> 15%
      EBIT / Enterprise Value-87.1%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-87.1%, ROC=None
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-903.51%
      ✗PiotroskiROA > 0
      ROA Change YoY-1527.10% -> -903.51% (delta: +623.59%)
      ✓PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-260.51%, ROA=-903.51%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity
      ✗Dreman> 12%
      Margin of Safety
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/4 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue
      ✗Ackman>= 15%
      Net Income / Shareholders Equity
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend
      ✗TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trend
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-220.83%; #5697/6340 (top 89.9%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-7.3990; #5670/5884 (top 96.4%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Valuation0% pass✓ 1✗ 27▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-87.1%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-87.1%, ROC=None
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per ShareN/A (negative BVPS)
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation Reasonableness
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical Average
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per Share
      ✗Ackman<= 25
      Price vs. Trailing Low100% of trailing low ($0.00)
      ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-220.83%; #5697/6340 (top 89.9%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization-6.0250; #6240/6449 (top 96.8%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-88.57%; #5965/6202 (top 96.2%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      FCF Positive and Growing
      ✗LynchPositive and growing
      Operating Cash Flow$-0.6M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-260.51%, ROA=-903.51%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap
      ✗Ackman>= 4%
      Price / FCF per Share
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/4 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✗ 13▾

      All 8 investors flag LUDG's growth

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue Growth
      ✗LynchInventory growth < Revenue growth
      EPS Growth Direction$-0.01 (2023) -> $-0.01 (2025)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/4 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth
      ✗Ackman>= 5%
      Positive EPS Growth Frequency1/2 years with positive EPS growth
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trend
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Verdicts0% pass✗ 14▾

      Split decision: 14 FAIL · 2 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (0/9)✗BuffettFAIL (0/9)✗LynchFAIL (0/7)•GreenblattNot ranked✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (0/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (0/6)✗MarksFAIL (0/5)✗AckmanFAIL (0/9)✗TempletonFAIL (2/8)✗SleepFAIL (1/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (0/6)✗SchlossFAIL (0/7)•OshaughnessyNEUTRAL (Not ranked)
    • Debt & Leverage8% pass✓ 1✗ 14▾

      11 of 12 flag LUDG's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: N/A (negative equity), IC: -11.1x
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / EquityN/A (negative equity)
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities0.05
      ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt LevelsN/A (non-positive equity)
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-19.3x, D/EBITDA=N/A (D&A unavailable)
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section
    • Efficiency13% pass✓ 1✗ 10▾

      7 of 8 flag LUDG's efficiency — Graham, Buffett, Greenblatt +4 more

      Current Ratio0.05
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)
      ✗Buffett> 10%
      ROIC - WACC
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)
      ✗Greenblatt> 25%
      Current Ratio Change YoY0.08 -> 0.05
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities0.05
      ✗Dreman> 1.5
      Return on Invested CapitalN/A (non-positive invested capital)
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)1/1 years above 12% (latest 108.9%)
      ✓SleepROIC > 12% in a majority of years

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Healthcare
    SIC Sector: Health Services
    Size: Micro Cap($668,667)
    Revenue: N/A
    Net Income: $2.2M+25.9% YoY

    Financial Snapshot

    Operating Margin--
    Return on Equity51.0%
    Debt / Equity-0.31
    Current Ratio0.05
    EPS (Diluted)$-0.01
    Shares Retired−0.6% / −4.6% 2y

    Shareholder Return

    Fiscal 2025

    Issued 0.6% of shares last year, 4.6% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-03-31

    2025-04-01 – 2026-03-31

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, net income, operating income, ebit, pre tax income, interest expense.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-03-16
    FY 2024
    Sources
    • 10-K · 2025-03-31
    FY 2023
    Sources
    • 10-K · 2024-04-16
    FY 2022
    Sources
    • 10-K · 2024-04-16
    FY 2021
    Sources
    • 10-K · 2024-04-16
    Market Cap$668.7Kcurrent--$8.1Mest.$21.2Mest.$44.8Mest.$110.3Mest.--
    Revenue------$217------
    Operating Income-$1.8M↓29%-$565.0K↓8%-$1.8M↓37%-$1.3M↑6%-$1.4M↓345%$560.5K--
    Net Income-$1.5M↑24%$218.8K↑140%-$2.2M↑26%-$3.0M↓23%-$2.5M↓155%-$965.1K--
    EPS (Diluted)--$0.00$-0.01↑50%$-0.02↓100%$-0.01----
    Gross Margin———————
    Operating Margin———-598243.8%———
    ROE36.7%↓48%—51.0%↓60%126.9%↓25%168.1%↑44%116.8%—
    Total Debt$1.4M↑105%$1.4M↑105%$1.4M↓30%$1.9M↑1849%$100.0K↓92%$1.2M↑807%$136.0K
    Shareholders' Equity-$4.0M↓46%-$4.0M↓46%-$4.4M↓85%-$2.4M↓63%-$1.5M↓77%-$826.2K↓1331%-$57.7K
    Current Ratio0.05↓43%0.05↓43%0.05↓33%0.08↑7%0.07↓81%0.38—
    Debt / Equity-0.35↓40%-0.35↓40%-0.31↑62%-0.82↓1098%-0.07↑95%-1.49↑37%-2.36
    Operating Cash Flow-$707.9K↓9%-$152.7K↓70%-$644.8K↑2%-$660.3K↓2%-$647.9K↓46%-$444.8K--
    Free Cash Flow--------------

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Healthcare

    LUDG vs Peers — Financial Grading

    RevenueN/A
    Net Income$2.2MBottom 25%
    ROE51.0%Top 25%
    D/E-0.31Median
    Op. Margin—
    Curr. Ratio0.05Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    HCA Healthcare, Inc.HCA$104.2B$499.05$75.6B$6.8B-112.6%-7.7113.0%0.971/95/93/71/3F-Score 64/11
    TENET HEALTHCARE CORPTHC$22.8B$286.03$21.3B$2.4B56.1%3.1216.5%1.761/94/93/73/3F-Score 65/11
    Guardant Health, Inc.GH$20.5B$151.70$982.0M$416.3M419.2%-15.14-44.5%4.842/91/91/70/3F-Score 52/11
    EXACT SCIENCES CORPEXAS$20.0B$104.91$3.2B$207.9M-8.7%0.00-6.4%2.432/91/93/70/3F-Score 73/11
    Fresenius Medical Care AGFMS$11.4B$22.03$23.1B$1.1B7.4%0.819.3%1.265/92/91/70/3F-Score 85/11
    UNIVERSAL HEALTH SERVICES INCUHS$11.2B$194.07$17.4B$1.5B20.5%0.6511.5%1.054/96/95/71/3F-Score 76/11
    DAVITA INC.DVA$11.0B$174.56$13.6B$746.8M-114.7%-15.7815.0%1.291/94/92/71/3F-Score 73/11
    CHEMED CORPCHE$7.1B$548.20$2.5B$265.2M27.1%—13.4%1.054/97/93/71/3F-Score 66/11